Top generic entry drug savings in Canada by public drug plan 2012/2013

This statistic depicts the savings for the top five generic entry drugs in Canada in fiscal year 2012/2013, distributed by public drug plan. In that year, savings for Nabilone (Cesamet) in Alberta's public drug plan amounted to 719,000 Canadian dollars.

Savings for top 5 generic entry drugs in select Canadian drug plans in 2012/2013

Public drug planRosuvastatin (Crestor)Candesartan (Atacand)Nabilone (Cesamet)Entacapone (Comtan)Bosentan (Tracleer)
------
------
------
------
------
------
------
------
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

March 2015

Region

Canada

Survey time period

FY 2012/2013

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Further Content: You might find this interesting as well

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.